Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3409 of 3445  at  11/27/2020 9:28:46 AM  by

Leverage01


Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Corcept Therapeutics (CORT) to $32 from $22 and keeps a Buy rating on the shares after the Patent Office Trial and Appeals Board issued a favorable decision regarding the post-grant review of Korlym patent 10,195,214. With the positive decision, Teva (TEVA) has a high hurdle to cross at the district court hearing that is currently scheduled in Q2 of 2021, Ramakanth tells investors in a research note. The analyst also thinks that with a "strong" PTAB decision that upheld all claims of the '214 patent, Teva may not prevail even if the company decides to appeal the PTAB decision to the Federal Circuit Court of Appeals.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...